EZH2 and neoplasm: miR-101 has been reported to upregulate EZH2 and thereby promote tumor growth, invasion, angiogenesis, and chemoresistance, whereas miR-137 and miR-138 downregulate EZH2, suppressing the malignant phenotype [163–166].